Orthofix has announced that Thomas West has been appointed to the company’s board of directors as well as to its compensation and talent development committee.
West currently serves as the president, chief executive officer and director of Intersect ENT, a commercial stage drug-device company. He led the transformation of the business, which resulted in a definitive agreement in August 2021 for Intersect ENT to be acquired by Medtronic for US$1.1 billion.
Catherine Burzik, chair of the Orthofix board, said: “Tom joins the Orthofix board of directors with more than 30 years of global experience in the medical device industry. We feel his vast experience will benefit Orthofix by providing international and domestic insights and guidance as we grow globally. We are very pleased he has chosen to join our board.”
Prior to Intersect ENT, West served as division president, diagnostic solutions at Hologic. Additionally, he had a 23-year career at Johnson & Johnson in various domestic and international roles across devices, pharmaceuticals and consumer products. He is also a member of the board of directors of the Advanced Medical Technology Association.
